Clinically, loss of BAP1 and CDKN2A expression can be useful ancillary markers for differentiating between cancer and reactive mesothelial cell proliferations [13] and are required for diagnosis of the recently established pathological entity malignant mesothelioma in situ (MMIS) [14]. Here, BAP1 is linked to cancer.